MorphoSys Announces First Scientific Publication on Novel Antibody Platform Ylanthia
News May 13, 2013
MorphoSys AG has announced that a first scientific publication on the Company's novel, proprietary antibody platform Ylanthia was published in the current issue of "mAbs".
The article titled "A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties" describes for the first time the detailed design, generation and testing of the Ylanthia library.
Ylanthia became commercially available for existing and new partners in 2012 and is currently used in two commercial agreements.
"Ylanthia sets new standards for therapeutic antibody generation. Its unique and innovative design translates into unprecedented structural diversity which is expected to result in antibodies against previously inaccessible target molecules and covering a unique epitope space. Furthermore, our scientists introduced an entirely new concept to improve biophysical characteristics that are relevant for antibody selection, manufacturing and administration, finally leading to better drugs," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.
To confirm the functionality and quality of the Ylanthia antibody library, phage selections against several antigens were performed.
Subsequent antibody characterization revealed broad diversity and significantly improved biophysical properties including a very low aggregation tendency, increased thermodynamic stability and favorable solubility of Ylanthia antibodies.
Ylanthia comprises more than 100 billion distinct, fully human antibodies, which makes it the industry's largest known antibody Fab library. It uses 36 fixed, naturally-occurring heavy and light chain framework combinations, which translates into very broad structural diversity.
Ylanthia's antibody frameworks were pre-selected for favorable expression levels, stability and aggregation behavior.
A shift towards higher stability and stress tolerance will increase shelf life and serum stability of resulting antibody products, making them more cost-effective to produce.
A higher solubility in turn opens up the path for more convenient ways of administration, to the benefit of patients.
When needed, antibodies from the Ylanthia library are optimized using MorphoSys's proprietary Slonomics technology.
Slonomics enables optimization of Ylanthia antibodies with unprecedented speed and flexibility.
Scientists from the UNC School of Medicine discovered that the anti-inflammatory protein NLRP12 normally helps protect mice against obesity and insulin resistance when they are fed a high-fat diet. The researchers also reported that the NLRP12 gene is underactive in people who are obese, making it a potential therapeutic target for treating obesity and diabetes.READ MORE